or
forgot password

Prospective Analysis of Percutaneous Ablations for Cancer Treatment


N/A
18 Years
N/A
Open (Enrolling)
Both
Cancer

Thank you

Trial Information

Prospective Analysis of Percutaneous Ablations for Cancer Treatment


The efficacy of the percutaneous and transarterial treatments for solid tumors will be
studied. Prospective study on patients who receive percutaneous locoregional therapies,
including radiofrequency ablation (RFA), cryoablation, microwave ablation, IRE and chemical
ablation for treatment of cancer will be performed.

Preoperative clinic chart, procedure note, postoperative chart, pre- and post-operative CT,
MRI or Ultrasound, angiographic findings, biopsy results and pathologic findings, will be
reviewed. Patient survival, treatment responses, complications after the therapy will be
collected from clinic visits and clinical encounters.

Patient overall performance status before and after procedures will be assessed using the
Quality of Life questionnaire (SF-36™ Health Survey).


Inclusion Criteria:



- 18yrs of age

- Cancer diagnosis

- Candidate for Locoregional therapy

- Willingness to sign informed consent

Exclusion Criteria:

- Unable to sign informed consent

- Patients not eligible for locoregional therapies

Type of Study:

Observational

Study Design:

Time Perspective: Prospective

Outcome Measure:

Effect of percutaneous and transarterial treatments for cancer in quality of life

Outcome Description:

Patients will complete the QOL questionnare during their follow up visits after procedure. 1 month, 3 months, 6 months and 1 year.

Outcome Time Frame:

1 year

Safety Issue:

No

Principal Investigator

Hyun S Kim, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Emory University

Authority:

United States: Institutional Review Board

Study ID:

RAD2160-11

NCT ID:

NCT01563679

Start Date:

February 2012

Completion Date:

December 2015

Related Keywords:

  • Cancer
  • cancer
  • locoregional therapies
  • RFA
  • Cryoablation
  • Microwave ablation
  • chemical ablation
  • Irreversible electroporation

Name

Location

Emory University Hospital Atlanta, Georgia  30322